In this video, Motley Fool health-care analyst David Williamson discusses what investors should look for in Biogen Idec's upcoming earnings report, and what the Big Biotech has in store for 2013.
Foolish Preview: Biogen Earnings
What investors should look for in Biogen's fourth quarter.
By Dave Williamson – Jan 26, 2013 at 8:31AM EST
Read Next
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Stocks Mentioned
Biogen
NASDAQ: BIIB
$184.61
(-0.16%)-$0.29
Teva Pharmaceutical Industries
NYSE: TEVA
$28.82
(-1.64%)-$0.48
Quest Diagnostics
NYSE: DGX
$201.02
(+0.07%)+$0.14
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.